Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 29, 2016 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer

--Study to Evaluate ONT-380 in Combination with Herceptin and Xeloda-- --Study Will Enroll HER2-Positive Breast Cancer Patients With and Without Brain Metastases-- SEATTLE, Feb. 29, 2016 (GLOBE...
January 11, 2016 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.

SEATTLE, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
December 08, 2015 16:05 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium

SEATTLE, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
December 02, 2015 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients

SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
November 16, 2015 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium

SEATTLE, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives...
November 05, 2015 16:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Reports Third Quarter 2015 Financial Results

SEATTLE, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the third quarter ended September 30, 2015. Net loss for the three months ended...
October 29, 2015 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Announces Third Quarter 2015 Financial Results Conference Call

SEATTLE, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 5, 2015 at 4:30 p.m. Eastern Time (1:30 p.m....
September 02, 2015 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon to Present at Rodman & Renshaw Annual Global Investment Conference

SEATTLE, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Rodman &...
August 06, 2015 16:01 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Reports Second Quarter 2015 Financial Results

SEATTLE, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the second quarter ended June 30, 2015. Net loss for the three months ended June 30,...
July 30, 2015 08:00 ET | Source: Cascadian Therapeutics, Inc.

Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call

SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time (1:30 p.m....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right